Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

9.750 +0.030 (+0.31%)
Streaming Delayed Price Updated: 10:35 AM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 Next >
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE Reports Results for the First Nine Months 2022 and Provides Corporate Update
Via ACCESSWIRE
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
Via ACCESSWIRE
Evotec Completes Acquisition of Central Glass Germany
Via ACCESSWIRE
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
Via ACCESSWIRE
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
Via ACCESSWIRE
Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen
Via ACCESSWIRE
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
Via ACCESSWIRE
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
Via ACCESSWIRE
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
From Toronto Innovation Acceleration Partners
Via Business Wire
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
Via ACCESSWIRE
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)
Via ACCESSWIRE
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
Via ACCESSWIRE
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
Via ACCESSWIRE
Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
Via ACCESSWIRE
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
From Alpine Immune Sciences Inc.
Via Business Wire
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
Via ACCESSWIRE
Evotec SE Reports Results of Annual General Meeting 2022
HAMBURG, GERMANY / ACCESSWIRE / June 22, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its shareholders approved all proposals the... 
From Evotec SE
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Evotec Enters a Drug Discovery Collaboration with Janssen
HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the Company has entered a drug discovery collaboration with Janssen... 
From Evotec SE
Via AccessWire
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING 
From Evotec AE
Via AccessWire
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) and Almirall S.A. (ALM), a global... 
From Evotec AG
Via AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and... 
From Evotec AG
Via AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
- 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS - COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING... 
From Evotec AG
Via AccessWire
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Evotec AG
Via AccessWire
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
- STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE - DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES - SUBSTANTIALLY... 
From Evotec AG
Via AccessWire
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
- THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB - EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A... 
From Evotec AG
Via AccessWire
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April... 
From Evotec AG
Via AccessWire
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
- FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC - PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR... 
From Evotec AG
Via AccessWire
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
- LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE - ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND... 
From Evotec AG
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
- EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL - THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN... 
From Evotec AG
Via AccessWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.